Mirati Therapeutics, Inc. (MRTX)

Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference, which will be web...

This Is Why Amgen's New Cancer Drug Could Be Huge

Biotechnology stocks are famous for dramatic price movements but smart investors have been eager to scoop up shares of Amgen (NASDAQ: AMGN) for a different reason. Despite its size, Amgen can move qu...

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and TaiwanMirati to receive an upfront payment of $65 million, up to approximately $273...

Amgen's (AMGN) KRAS Inhibitor Gets FDA Nod for Lung Cancer

FDA approval of Amgen's (AMGN) Lumakras for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer is based on positive data from the phase II CodeBreaK 100 study....

Companies Like Mirati Therapeutics (NASDAQ:MRTX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and......

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.